Get started

Biotech

$CDTX can rise in the next daysContextual immersion trading strategy idea. Cidara Therapeutics is a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases The demand for shares of the company looks higher than the supply. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,82; stop-loss — $2,59. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CDTXLong
by KozakHlib
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains. Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective. I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time. Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
NASDAQ:NVAXLong
by ChristopherCarrollSmith
5
$CHMA can rise in the next daysContextual immersion trading strategy idea. Chiasma focuses on developing oral medications using a transient permeability enhancer technology platform for the treatment of rare and serious chronic diseases. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $4,05; stop-loss — $3,96. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CLong
by KozakHlib
$IMMU can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Immunomedics looks higher than the supply. It is a clinical-stage biopharmaceutical company, which develops monoclonal antibody-based products for the targeted treatment of cancer. On 06APR the company announced that its Phase 3 confirmatory ASCENT study will be halted due to compelling evidence of efficacy. This drug has the potential to be the first FDA-approved conjugate for the treatment of metastatic triple-negative breast cancer — finance.yahoo.com This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $19,37; stop-loss — $18,60. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
ILong
by KozakHlib
$CBPO can fall in the next daysContextual immersion trading strategy idea. The demand for shares of China Biologic Products Holdings looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $99,86; stop-loss — $102,65. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CShort
by KozakHlib
$MNOV can rise in the next daysContextual immersion trading strategy idea. The demand for shares of MediciNova looks higher than the supply. The company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $4,41; stop-loss — $4,21. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MNOVLong
by KozakHlib
$ATOS can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Atossa Therapeutics looks higher than the supply. The company develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,58; stop-loss — $1,50. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ATOSLong
by KozakHlib
2
Is $MBRX- The Best Biotech with the most upside Potential Is $MBRX- The Best Biotech with the most upside Potential Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and $MBRX break through with STAT3 inhibitors is a game-changer for treating cancer patients. As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term.. One you might want to research and stick away in your IRA .. As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
NASDAQ:MBRXLong
by InvisbleHand
1
$ASND can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Ascendis Pharma A/S looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $117,86; stip-loss — $114,88 Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ASNDLong
by KozakHlib
ACST is now in the spotlightSo today I sold my NCLH and Bitcoin and went into ACST or Acasti Pharma. We made nice gains with NCLH with a killer premarket but leveled off back under closed, but than exploded 6% and going even higher after I sold at 11.22 with my buy at 9.88. Bitcoin has been bouncing between 1-2%, which had nice support at the emas this morning. is why ACST also caught my eye. How did i hear about ACST well someone brought up that Amarin or AMRN open 60% down with ending in a 70% lose today and ACST is its competitor, with it being in penny stock territory. ACST also has gone to the FDA planning on getting in meetings to move on with their drug, I think Its CaPre which is "CaPre is intended to be used as a therapy in conjunction with positive lifestyle changes including diet, and is to be administered either alone or with other drug treatment regimens such as statins (a class of drug used to reduce cholesterol levels). " Which this market is a 50billion dollars with this stock being about 35million dollars valuation with the company owning about 90million and public owning about 70million shares. With their drug ending its testing phase its now up to ACST to work with the FDA, which could happen anytime between now or in 70days is how long till a respose will take for the FDA. There is a high chance it will get approve from many spectators. Now technicals -AMRN got hit hard, yet ACST hasn't moved much but its penny stock. -From its low to now its up about 49%, yet from were its been trading at the $2.30ish is down 82%, so hugh upside with a 450% gain back to original trading range with it going higher as of $3 before the sell preasure hit. ($3 was the original target from what I read with a target in the $8 range if the FDA approves of the drug) -MACD on the hourly is bearish -Volume is very low which we could expect a big move soon -RSI is heading towards overbought, yet its netural to me -So far on active hours and premarket its holding the 50ema on the hourly, yet we would need a break above the others. maintaining above the the 50ema is always a bullish sign, yet it will need to hold and see upward price movement. I'm a long buyer just cause the price is near its lowest even though it could go lower, yet I don't see much more room to drop with the marketcap. We would have to wait till premarket tonight for this stock and hopefully its bullish.
ALong
by nathanielx9
$AYTU can rise in the next daysContextual immersion trading strategy idea. Aytu BioScience has a strong upward trend. The company develops and commercializes novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility. Due to the spread of the COVID-19, the demand for the company's services rose. Today Aytu BioScience received confirmation from the FDA that it may begin distribution of its COVID-19 IgG/IgM Rapid Test throughout the U.S. — finance.yahoo.com This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,85; stop-loss — $1,65. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:AYTULong
by KozakHlib
2
$GILD can rise in the next daysContextual immersion trading strategy idea. Gilead Sciences has a strong upward trend. The company is developing a treatment for COVID-19 now. Due to the spread of the virus, this company looks very attractive and has a potential for success. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $80,74; Information about stop-loss and take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:GILDLong
by KozakHlib
GILEAD In the LeadCharting historical Support and Resistance levels. Gilead was on track to have an improved 2020 financials wise even before Corona Market. They are the front runner for vaccine in terms of drugs already in trials to treat similar COVID diseases. They also have two drugs being tested and waiting to be approved in China for cancer drugs which will continue to bolster stock if looking to hold long term. Many smaller biotech stocks with few to no results were losing value even in the bull market of last few months, now once Corona fears subside or companies have patented successful drugs, those companies will go back to losing their value and I think player like GILD are here to eat that up for those still looking to invest in biotech, but not penny stocks. Considering how manic this run up has been, the tests at the historical levels have been met and beaten, just not for as long as we'd like to see. Seems likely to have a small correction 03/09 as it's now at the level it was previously brought down sharply, but if mooning through 82.50 without dropping below 78.50 then it's clear to have another discovery between 85-90. Summary: Good long term investment. Good swing trade. Scalping could cause a shortened lifespan, though huge room for profit (and loss =D)
NASDAQ:GILD
by DiscountedCokeFlow
Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019). Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly. Disclaimer: This is not financial advice. Just my own opinion based on research. Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.
NASDAQ:NVAXLong
by traderman001
2